Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

AstraZeneca Anticoagulant NDA Delayed; Crestor v. Lipitor Data In March

  • News

Executive Summary

AstraZeneca plans to submit an NDA for the oral direct thrombin inhibitor H376/95 in the second half of 2002.

You may also be interested in...



Pfizer ACAT Inhibitor Phase III Underway; Zocor, Lipitor Prepare For Crestor

Pfizer will receive Phase III data on the anti-atherosclerotic agent avasimibe during 2001, Worldwide Development President Peter Corr told a Pfizer securities analysts meeting Dec. 11 in New York City.

Pfizer ACAT Inhibitor Phase III Underway; Zocor, Lipitor Prepare For Crestor

Pfizer will receive Phase III data on the anti-atherosclerotic agent avasimibe during 2001, Worldwide Development President Peter Corr told a Pfizer securities analysts meeting Dec. 11 in New York City.

AstraZeneca Symbicort U.S. Filing Awaits Results of Formoterol Trials

A U.S. NDA filing for AstraZeneca's combination asthma therapy Symbicort awaits completion of Phase III trials of the beta agonist (formoterol) component.

Table

View full table

Tags:
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS037040

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By